009420.KO Hanall Biopharma
- Market cap
- KRW 2.01T
- P/E
- -
- P/B
- 11.69x
- ROE
- -23.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 009420.KO undervalued?
Graham numberThe Graham number of Hanall Biopharma cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hanall Biopharma fundamental analysis
No fundamental analysis for Hanall Biopharma yet.
Hanall Biopharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, …
Full company profileHanall Biopharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hanall Biopharma annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 82.9B | 84.2B | 91.8B | 108B | 88.6B | 102B | 110B | 135B | 139B | 155B | 169B |
| Gross Profit | 38.5B | 42.7B | 49.0B | 62.8B | 50.7B | 60.3B | 62.0B | 75.2B | 73.3B | 80.9B | 92.2B |
| Operating Income | 285M | 3.54B | 5.47B | 17.1B | 5.94B | 10.1B | 1.51B | 2.21B | 230M | -916M | 12.9B |
| EBITDA | - | 5.70B | 7.46B | 20.2B | 22.1B | 11.5B | 5.00B | 6.51B | 3.01B | -2.48B | -37.1B |
| Net Income | 2.03B | 5.81B | 3.30B | 19.2B | 19.8B | 8.90B | 251M | 3.51B | -1.80B | -5.56B | -37.9B |
| EPS | - | 114 | 64 | 375 | 386 | 174 | 4.96 | 69 | -36 | -109 | -746 |
| Balance Sheet | |||||||||||
| Total Assets | 125B | 169B | 162B | 191B | 220B | 198B | 213B | 240B | 213B | 225B | 241B |
| Total Liabilities | 20.4B | 57.5B | 45.4B | 51.0B | 38.9B | 35.0B | 45.2B | 53.5B | 44.5B | 63.5B | 78.9B |
| Shareholders' Equity | 104B | 111B | 117B | 140B | 181B | 163B | 168B | 186B | 168B | 162B | 162B |
| Cash & Short-term Investments | 9.50B | 41.9B | 22.7B | 6.12B | 4.20B | 12.8B | 16.8B | 33.7B | 16.4B | 24.7B | 30.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.95B | 42.1B | -2.99B | 20.5B | 929M | 840M | 25.2B | 29.6B | 9.36B | -2.34B | -8.41B |
| Capital Expenditure | 4.03B | 1.73B | 1.92B | 2.12B | 2.56B | 4.61B | 2.83B | 9.20B | 23.1B | 14.1B | 10.6B |
| Free Cash Flow | - | 39.9B | -4.91B | 12.2B | -6.46B | -8.16B | 17.5B | 20.4B | -13.7B | -16.5B | -19.0B |
| Ratios | |||||||||||
| ROE | 1.9% | 5.2% | 2.8% | 13.7% | 10.9% | 5.4% | 0.1% | 1.9% | -1.1% | -3.4% | -23.5% |
| ROA | 1.6% | 3.4% | 2.0% | 10.0% | 9.0% | 4.5% | 0.1% | 1.5% | -0.8% | -2.5% | -15.8% |
| Net Profit Margin | 2.4% | 6.9% | 3.6% | 17.7% | 22.3% | 8.8% | 0.2% | 2.6% | -1.3% | -3.6% | -22.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hanall Biopharma dividends
Hanall Biopharma has not paid dividends in the last 9 fiscal years.
Last stock split: 10:1 on May 3, 2006.
Who owns Hanall Biopharma
- Insiders 31.67%
- Institutions 17.06%
- Public & others 51.28%
- Shares outstanding 50.9M
- Free float 34.5M
Hanall Biopharma company profile
- Company name
- Hanall Biopharma
- Ticker
- 009420.KO
- ISIN
- KR7009420001
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 287
- Fiscal year end
- December
- Address
- 43, Sangseodang 1-gil, Daejeon, South Korea
- Phone
- 82 42 932 5997
- Website
- hanall.co.kr
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.
Hanall Biopharma management
8- Mr. Seung-Kook Park M.B.A., Ph.D.Co-CEO & Director · born 1963
- Mr. Su-Jin ParkCo-CEO, VP & Director · born 1972
- Mr. Christopher W. SlavinskyChief Business Development & Legal Officer · born 1973
- Nam-Yong ChoSenior Executive Director of Sales & Marketing and Senior Managing Director · born 1954
- Mr. Jae-Seung YoonC.V.O · born 1962
- Ms. Hye Kyung AhnHead of Research Division · born 1971
- Mr. SeongUn KimHead of Business Management Division · born 1980
- Mr. David HernandezVP & Head of Clinical Development Operations